Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Virus Diseases 1Liver Cirrhosis 1Hepatitis, Viral, Human 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × hepatitis C immune globulin, human × Clear all
NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Biotest Pharmaceuticals Corporation

Phase 3 Completed
80 enrolled
Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡